Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

CME

Inflammatory Breast Cancer

There is no time at which patients can be completely assured that the disease will not recur.
CME credit is no longer available for this conference.

Course Authors

Robert G. Lerner, M.D.

In the past three years, Dr. Lerner has served as a consultant for RPR, and has served on the Speakers' Bureau for Pharmacia & Upjohn.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Describe the clinicopathologic entity of inflammatory breast cancer

  • Discuss the prognosis for women with inflammatory breast cancer

  • Explain the dramatic improvement in prognosis since the introduction of modern combined modality therapy

  • Discuss the availability of and controversy surrounding the use of autologous bone marrow transplantation for breast cancer.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

AML2

Estimated Time: 6 Hours
More

Emerging Treatments In Acute Myeloid Leukemia (AML)

Several investigational agents offer hope to patients with AML.
Authors: Mary-Elizabeth M. Percival, M.D., M.S. and Roland B. Walter, M.D., Ph.D., M.S.
Estimated Time: 1 Hour
More

Unexplained Bleeding in Hospitalized Patients

While some disorders are more readily apparent than others, not all bleeding is straightforward or has a readily identifiable cause.
Authors: Meera B. Chitlur, M.D.
Estimated Time: 1 Hour
More

Lung Cancer Chemoprevention

Despite advances in lung cancer chemotherapy, there is a pressing need for effective lung cancer chemoprevention beyond smoking cessation.
Authors: Robert L. Keith, M.D.
Estimated Time: 1 Hour
More

Molecularly Targeted Therapy for Malignant Brain Tumors

Neuro−oncology is focusing on the uses of molecularly targeted agents in the adjuvant setting.
Authors: Nicole A. Shonka, M.D., and Mark R. Gilbert, M.D.
Estimated Time: 1 Hour
More